AbbVie (NYSE: ABBV) today announced plans to launch ELAHERE® (mirvetuximab soravtansine-gynx) in the U.K. at a list price equal to the U.S., reflecting the advanced innovation and value of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback